What are the currently approved treatment indications for Pimitespib?

Pimitespib An oral small moleculeHSP90 (heat shock protein 90) inhibitor, developed by Japan's Taiho Pharmaceutical, is one of the few HSP90 targeted therapies in the world that has successfully entered clinical practice and obtained marketing approval. Its main mechanism of action is to inhibit HSP90, a molecular chaperone protein, thereby destroying the stable dependence of tumor cells on multiple oncogenic proteins and inducing cell apoptosis. Unlike other targeted drugs, pimotebi does not specifically target a certain type of mutation or a single pathway, but achieves anti-tumor effects by affecting the protein functions of multiple signaling pathways. Therefore, it has potential application value in some solid tumors with complex drug resistance mechanisms.

So far, pimetibi has been approved in Japan for the treatment of gastrointestinal stromal tumor (GIST), especially for patients who have previously received standard treatments (such as imatinib, sunitinib, regorafenib, etc.) but still experience disease progression. GIST is a rare solid tumor originating from the stromal tissue of the gastrointestinal tract wall. Its onset is highly related to KIT or PDGFRA mutations. Although targeted drug therapy has made significant progress, there is still a significant problem of secondary drug resistance. The approval of pimetibib was based on its potential to provide disease control after failure of multiple lines of therapy, bringing an important new treatment option to these patients.

According to public information, the approval of pimotebi mainly relies on the results of a Japanese phase III clinical study calledCHAPTER-GIST-301. The study showed that the drug can effectively delay disease progression and is well tolerated. Although the specific PFS or OS data have not been fully disclosed, it is enough to obtain approval from the Japanese drug regulatory agency. Currently, its trade name is Jeselhy, its specifications are 40mg capsules, and it is administered once a day.

Reference materials:https://en.wikipedia.org/wiki/Pimitespib